This is going to be hugh in the next few weeks after approval is got for first product.........
HIV.ob
Calypte Biomedical Receives Final Report From China Clinical Trials Tuesday September 6, 9:25 am ET
LAKE OSWEGO, Ore., Sept. 6 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV - News) today announced that it has received the final clinical trial report from the Chinese Centers for Disease Control (Chinese CDC) confirming the performance of the five Calypte HIV tests that were evaluated earlier this year. Three rapid HIV tests, Aware HIV-1/2 BSP, Aware HIV-1/2 OMT, and Aware HIV-1/2 U were evaluated in these studies. These tests employ, respectively, blood, oral fluid, and urine samples. In addition, the Calypte HIV-1 Serum Western blot and the HIV-1 Urine Western blot tests were evaluated for their performance in various Chinese provinces and populations. The clinical trial was performed by the Chinese CDC. The clinical trial of the three rapid tests included 1506 subjects; 247 of whom were infected and 1259 of whom were uninfected. The table below summarizes the performance of the rapid tests.
Sensitivity is a measure of the number of infected subjects correctly identified as positive. Specificity is a measure of the number of uninfected subjects correctly identified as negative. Accuracy is a composite measure of how many of the test subjects were correctly classified as infected or uninfected.
The serum and the urine HIV-1 Western blots also performed well, with sensitivities of 100% and 98.4%, respectively. The specificity of the urine Western blot was 100% and the specificity of the serum Western blot was 99.4%. The specificity of the serum Western blot was less than 100% as a result of two HIV-negative subjects whose sera displayed bands for p24, resulting in a so-called "indeterminate" interpretation. The presence of p24 antibodies is a common occurrence in uninfected individuals, and indeterminate results should not be confused with false positive results.
Dr. Richard George, President and CEO of Calypte said, "We are extremely encouraged by the excellent outcome of the China clinical trial. The Chinese CDC did an admirable job of conducting these studies and preparing the report. We now believe that all three rapid assays are approvable and that the OMT and urine tests are eligible for accelerated review. As I stated in our most recent conference call on August 15, the first application we file will be for approval of the Aware HIV-1/2 OMT test. We expect to make the submission in the coming weeks. The OMT application will be followed shortly by a submission for the Aware HIV-1/2 Urine test."
Dr. George continued; "Work in China continues at a vigorous pace to prepare for the impending launch of our sales effort after receipt of SFDA approval. Dr. Ron Mink, Calypte's Chief Science Officer, and members of his scientific staff are currently at our manufacturing facility near Beijing training our staff to make the rapid assays. We are also expecting delivery and installation of automated manufacturing equipment in early September. It is very gratifying to see all of our hard work resulting in a successful conclusion."
About China:
China has a population of approximately 1.4 billion. According to a joint China, World Health Organization and UNAIDS epidemiological survey there were 840,000 adults and children in China living with HIV/AIDS in 2003. In July of 2004, the Chinese premier, Wen Jiaboa went so far as to acknowledge HIV/AIDS as one of the "serious problems" facing China. Some experts have predicted that the number of infections by that date might exceed 15 million. Most experts agree that testing and education are the most important things that can be done to stem the spread of HIV/AIDS. To that end, the Chinese government has recently announced its commitment to offer voluntary HIV testing to its entire 1.36 billion-population. In countries where HIV infection has been contained, according to UNAIDS estimates, annual testing rates of the population aged 15-64 that is tested in a non-blood bank setting is between 15% and 25%. To effectively combat the spread of infection and meet the goals they have set for themselves, we believe that China must bring testing rates up to these levels and that this can only be done by the use of simple, inexpensive, and safe tests that can be performed on non-blood samples such as oral fluid and urine. Such tests can be performed in large numbers by non-medical personnel in all types of non-traditional settings.
About Calypte Biomedical:
Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent filings with the SEC.
Investor Relations Contact: www.calypte.com Posted by crusader30 on :
I don't know who you are stranger but you called this one right. I got in at .20. This could be a nice ride. I'd been watching it earlier. We'll see where it goes.
Posted by R1Man on :
Hey, bad news is....they just joined the amex 8-16-2005. Most stocks that come out of pinks get raped. I would sit back and look for a dip before I bought any. I think the news is good.....but its not like the tests are going to be available anytime soon. They always have to get approvals for public sale. So on that token....it might be a while before we see this one take off....long term....Your make lots of money. Short term....not likely.
Posted by metal1 on :
actually, they joined the Amex 8-18-2004. the 05 headline was for continued listing.
Posted by R1Man on :
quote:Originally posted by metal1: actually, they joined the Amex 8-18-2004. the 05 headline was for continued listing.
Ok....but does 2 days really matter. I was just looking at the news when I got the date.
Posted by crusader30 on :
Not bad, up 38.89% today. I can live with that. Very Interesting Company. Posted by Topcat on :
They will make a submission in the coming weeks.
Might not take to long to get approval in China...
The product is packed and ready to ship apparently.
Chinese government has recently announced its commitment to offer voluntary HIV testing to its entire 1.36 billion-population.
Posted by Topcat on :
Up 16% in pre market.......
Posted by metal1 on :
not 2 days, one year, it was listed on 04 not 05. man.
Posted by Topcat on :
.31 nice......
Posted by bdgee on :
.33 now
Posted by Topcat on :
probably goin to hit .39-.40 by close of day
Posted by crusader30 on :
Topcat, my hats off to you. Posted by Topcat on :
Some big buys going through.... Somthing in the air.
Big PR tomorrow am ??
Posted by Topcat on :
News out!!!!!!!!
-Sep-2005
Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Contract. Effective on September 1, 2005, Calypte Biomedical Corporation ("the Company") entered into an agreement (the "Agreement") with Marr Technologies Asia Limited ("Marr"), a Seychelles company, to define the respective rights, duties and obligations of the parties in connection with the ownership and operation of Beijing Calypte Biomedical Technology Ltd. ("Beijing Calypte"), a joint venture entity created in the Peoples' Republic of China ("China") to manufacture, market, distribute and sell certain of the Company's current and future products in China. Marr is an affiliate of Marr Technologies BV, a Netherlands company, which currently owns approximately 27% of the Company's outstanding common stock.
The Agreement authorizes a five-member Board of Directors which is responsible to manage the business, property and affairs of Beijing Calypte in accordance with the provisions of the Agreement, Beijing Calypte's Amended and Restated Articles of Association and all applicable laws. The Board is composed of three directors designated and appointed by Calypte, each for a four year term, and two directors designated and appointed by Marr, each for a four year term. Each Director shall cast one vote on each resolution to be voted upon. The Agreement further specifies certain major decisions, such as incurring indebtedness, merging Beijing Calypte with another entity, acquiring another entity or dissolving Beijing Calypte, among others, which require unanimous vote by the Board of Directors.
The Agreement provides, with only limited exceptions, that neither Marr nor the Company has the right to transfer its interest in Beijing Calypte to any other entity. The Agreement will remain effective until it is terminated upon the mutual agreement of Marr and the Company or upon a resolution of the Board of Directors of Beijing Calypte or an order by a court of competent jurisdiction for the winding down of Beijing Calypte's business affairs.
Posted by Topcat on :
.3 close
Posted by crusader30 on :
Correction Topcat, it only closed up .03 (12%) Posted by Topcat on :
Was up 40% at .35 at one stage.....
another pop this am and im out .36.
Will get back in later.
Posted by crusader30 on :
Topcat, This one looks primed for long term swing plays. Everyone should make alot of money. I'm in at .20 so I'm up 40% at close yesterday. And, It's at .29 after hours.
Again thanks for the timely posting of this topic
Posted by Topcat on :
In at .17 should have taken $$ yesterday. But held for .36.
Posted by crusader30 on :
Topcat, all in all it's been a great week ending @.27 with a high of .35
Posted by Topcat on :
Yea, Your right shouldn't be so anxious for the big pay day in just a few days.....
Lets see what next week brings.
Posted by crusader30 on :
Topcat, so far the week has brought a .01 increase in PPS. Which is a 3.7 % increase over yesterday.
But, the weeks not through.
Anyone want to calculate it 5% increase per week, compounded?
Posted by Topcat on :
May not see any great gains this week. Unless we get some news on the submisssion to China.
But I think that may be a few weeks off. For the time being I'd be happy to sit around .25-.28 range.
TC
Posted by bdgee on :
$1000 at 5% per week, compounded, becomes $12642.81 after 0ne year
Posted by RICKBIN57 on :
HI GUYS. I'M A NEW INVESTOR AND JUMPED HEAD FIRST INTO CALYPTE,(HIV). I BOUGHT 364,672 SHARES. SOME AT .28 AND THE REST AS I COULD AQUIRE YESTERDAY, 9-12-05. THIS THING IS GOING TO MAKE A TON OF MONEY! I'VE RESEARCHED EVERY SEARCH ENGINE I COULD FIND AND THE WORD IS: 66% INCREASE BY YEARS END, DEC.2005, UP 200% YEAR END 2006. 60-90 DAYS FOR THE APPROVAL PROCESS SFDA(CHINA), WAITING FOR APPROVAL FROM OUR FDA, EST.120 DAYS. BASICALLY WE'LL HAVE A MONOPOLY IN THE CHINESE MARKET. THE CHINES GOVERNMENT HAS A SFDA APPROVED PLANT UP AND RUNNING MAKING THE TEST KITS,NOW! ORDERS FROM THE 3rd WORLD COUNTRIES ARE ARRIVING. ROCKADLE MARYLAND PLANT APPROVED AND UP AND RUNNING, PRODUCING KITS, NOW! THE PLANT ITSELF HAS BEEN SOLD TO ANOTHER COMPANY, REDUCING OVERHEAD AND COSTS BIG TIME! NEW MANAGMENT, RESTRUCTURED PLAN, REDUCED OVERHEAD, AND A VIRTUAL MONOPOLY IN CHINA. YOU'RE GOIN' TO MAKE A FORTUNE,IF YOU ARE PATIENT. TO ME, THIS IS A ONCE IN A LIFETIME OPPORTUNITY. I HAVE RESEARCHED THIS COMPANY UP AND DOWN. IT'S JUST GOING TO TAKE A LITTLE TIME. THIS STOCK HAS ALL THE POTENTIAL TO HIT $5.00 IN A YEAR, YEAR AND A HALF. IN MY HUMBLE OPINION.
Posted by RICKBIN57 on :
I NEED ALL THE FEEDBACK I CAN GET. THIS COMAPNY IS NOT THE OLD CALYPTE, IT IS COMPLETELY RESTRUCTED. AND HAS AND UNUSUALLY GOOD RELATIONSHIP WITH CHINA. THIS MAY BE THE BIG ONE.
Posted by Topcat on :
Rickbin, Sounds like you have completed the same research as I have.
$5 a share sounds Like a very long term goal....
367,672 @ .28 = $102000 some investment, 10 times what I'm in for.
Where did you first hear about Calypte ?
Posted by crusader30 on :
This is just sweet. A nice steady movement. Nice news. What's not to like about HIV (except having it.) Posted by Topcat on :
Must agree with you crusader, probably better long term to have small moves in pps not leaving gaps to fill.
Keep this up for the rest of the week and we'll be sitting pretty.......
TC
Posted by crusader30 on :
Topcat, it appears we have settled within a narrow range and established a new floor. The initial day traders have taken their profits. Let's wait on the next PR. Good luck Posted by bdgee on :
Big news.... HIV-1/2 BSP Test Receives Zimbabwe Approval. Up 25+% in premarket
Posted by Topcat on :
News out !!!!
Up 25% in pre market..... Goin to be a good day.
TC
Aware(TM) HIV-1/2 BSP Test Receives Zimbabwe Approval Thursday September 15, 8:41 am ET Regulatory Trials Of Aware(TM) BSP Generate 100% Accuracy
LAKE OSWEGO, Ore., Sept. 15 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV - News) today announced that the Medical Laboratory & Clinical Scientists Council of Zimbabwe has issued notification that the Calypte Aware(TM) HIV-1/2 BSP rapid (blood) test has been successfully evaluated and cleared for commercial sale in Zimbabwe. The Calypte Aware HIV-1/2 BSP rapid test was evaluated under the direction of the Medical Laboratory & Clinical Scientists Council of Zimbabwe on over 1,000 samples. Roughly half of the samples were archived samples from the national reference panel and the other half were collected prospectively from clinical patients, blood donors, and attendees at VCT (Voluntary testing and Counseling) sites. The clinical trial of the Aware HIV-1/2 BSP rapid test included 1,005 subjects; 224 of whom were infected and 781 of whom were uninfected. The table below summarizes the performance of the rapid tests.
Sensitivity is a measure of the number of infected subjects correctly identified as positive. Specificity is a measure of the number of uninfected subjects correctly identified as negative. Accuracy is a composite measure of how many of the test subjects were correctly classified as infected or uninfected.
Calypte and its distributor, National Diagnostics, are now working with authorities on a process by which Aware HIV-1/2 OMT (oral fluid) and HIV-1/2 U (urine) rapid assays can be evaluated. Zimbabwe has not had the opportunity to field test non-blood HIV screening tests before, and its standard approach to evaluate HIV antibody tests is not appropriate for samples such as urine and oral fluid. The authorities are examining various proposals for such an evaluation.
Dr. Richard George, President and CEO of Calypte said, "We are delighted that the BSP test has passed yet another regulatory hurdle, and we now look forward to working with National Diagnostics, our distributor in Zimbabwe, to get the product commercially launched. In parallel we hope to complete the evaluation using the Company's technology in Urine and Oral fluid."
Tony Mariani, President of National Diagnostics, added, "We are extremely pleased with the exceptional results achieved by the Aware BSP HIV-1/2 kit in its evaluation phases. We look forward to our venture with Calypte in the marketing and distribution of this kit throughout Zimbabwe. Since our establishment in 1991, National Diagnostics has imported and distributed a wide range of diagnostic reagents, and this project promises to be one of the most important undertakings in our company's history".
Zimbabwe, with a population of just under 13 million, has an estimated 1.8 million HIV infections, according to the UNAIDS 2004 Report on the Global AIDS Epidemic, ranking as the 3rd largest prevalence in Africa today.
Aware(TM) BSP is a twenty-minute rapid test designed to detect HIV antibodies in whole blood, serum, or plasma. It is one test in a line of three such assays, the other two being designed to detect HIV antibodies in oral fluid and uri
Posted by Topcat on :
No great movement, was up 25% premarket, but never made it??
Any idea why ?
Posted by crusader30 on :
Topcat, you beat me to it again. Don't have a clue but I believe they are doing all the right things. Posted by Topcat on :
Seems only news on China will move us again.
Or maybe some actual sales in Africa.....
Posted by crusader30 on :
Topcat, I put this on my regular broker yesterday. He got back with me latter in the day to say he is very impressed. One of the things he was most impressed with was MARR.
He wasn't that worried about the number of outstanding shares because MARR owns 27% of the company and ready to handle China. This was a major plus.
Posted by crusader30 on :
Excellent reaction from my broker. Never thought it would happen in my lifetime.
Posted by R1Man on :
quote:Originally posted by Topcat: No great movement, was up 25% premarket, but never made it??
Any idea why ?
I'd feel lots better if it wasn't a AMEX stock. For that reason I think the stock has to show earnings before you get any real jumps. Good luck.
Posted by Topcat on :
Up 28% in premarket, lets hope it actually makes it today......
Posted by R1Man on :
LOL......look at the daily high today....I think the guy was the daily high too.
$1,000.00......what a jack @ss.
Posted by R1Man on :
R1MAN, You got it right. I guess he got a very very very strong buy signal from the HOOKA he was sitting in front of.
Talk about screwing up your charts for the next month. Forget candlesticks.
Posted by crusader30 on :
The company will host a conference call featuring a report by its Chairman and interim Chief Executive Officer, Roger I. Gale, at 11:00 AM Eastern Time on Friday, October 14, 2005, followed by a question and answer session. The call can be accessed in the U.S. by dialing 1-800-573-4842 and outside of the U.S. 1-617-224-4327 and entering conference identification number 65101749.
Posted by Topcat on :
THanks Crusader, hopfully the PPS won't drop anymore between now and then.
Should have some news on China.
Posted by crusader30 on :
Topcat, there's so much news I don't know where they will start. I guess everyone wants an update on the plant in China and the China CDC. Next would be the Manufacturing facility in the US. Then the state of the Africian nations. Last (but probably first) would be the new management team. A lot have been said about MARR taking over for sales and marketing now that the Scientific part is essentially finished. Posted by Topcat on :
Let's hope its not just the new mangement this call is about....
I won't be able to call in, pls update with info ??
Posted by crusader30 on :
Absolutely. Posted by Topcat on :
More good news yesterday.... sorry for the late post.
Press Release Source: Calypte Biomedical
Calypte Aware(TM) BSP Passes Malaysian Government Evaluation Tuesday October 11, 8:30 am ET
LAKE OSWEGO, Ore., Oct. 11 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV - News) today announced that it has received notification that Aware(TM) BSP, its rapid blood test for HIV-1 and HIV-2 antibodies, has been successfully evaluated by government agencies in Malaysia. ADVERTISEMENT
In Malaysia, favorable government evaluation is generally requested although not strictly required to market HIV tests.
Aware(TM) BSP is a twenty-minute rapid test designed to detect HIV antibodies in whole blood, serum, or plasma. It is one test in a line of three such assays, the other two being designed to detect HIV antibodies in oral fluid and urine. The health authorities in Malaysia have not evaluated non-blood HIV tests in the past, and are determining how such evaluations should be undertaken.
"We're delighted our Aware HIV-1/2 products continue to perform well in clinical evaluations around the world. Now that the Aware BSP test has passed this evaluation, we look forward to working with Belantara Sains Teknologi (BST), our Malaysian distributor, to commercially launch the product," stated Roger Gale, Calypte's Chairman and Chief Executive Officer.
Christine Lim, BST's Chief Operating Officer, added, "The support that we had from Calypte Biomedical prompted us to have these kits evaluated via a recognized body. This has created a higher confidence for our customers who have had some bad experiences from the unevaluated kits which are so vastly available in this eastern part of the world. Now we can look forward to working more closely not only with the Ministry of Health but especially with the health clinics in the remote areas, where a kit as convenient as this is certainly useful, practical and most importantly, reliable."
Malaysia, with a population of roughly 24 million, has an estimated 55,000 HIV infections, according to the CIA Fact book, 2003.
About Calypte Biomedical:
Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Posted by Topcat on :
Con-call Today at 11am.
Some big buys yesterday at the bell.
Posted by crusader30 on :
Topcat, The CC was a non-event. Little was learned. The new players were introduced, period. The real CC will be mid-november. We should have financial news at that time. Posted by crusader30 on :
Time to bring this thread up again. Movement today was to .23 on no news, nothing, NADA. Beats the hell out of me. But since I'm in as a long holder it's nice to see movement of this kind. Posted by Topcat on :
Plenty rumours around, nothing solid yet, somebody knows something 43 % yesterday on no news. Most of the buys at the bell.
Got to have got China approval.....
Posted by kywee on :
got my eye on it. premarket buys going through at 8:28 am
Posted by Poker Time on :
Dumped my shares months ago at 19cents a share...WTF is going on here?
Posted by crusader30 on :
Poker, I wish I knew. But someone knows and they're acting on it. Or, this is a buying frenzy by folks that don't want to get left out. I'm going to hold till news about China, etc. This isn't a short term stock IMO. Posted by Topcat on :
Chian approval received, goin to be hot today !!!
Calypte Announces Submission of Application to Chinese SFDA Thursday January 12, 8:00 am ET For Approval of its Aware(TM) OMT Oral Fluid HIV-1/2 Rapid Diagnostic Test
LAKE OSWEGO, Ore., Jan. 12 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV - News) today announced that it has received notification from the Beijing Drug Administration (BDA) that its application for approval in China of its Aware(TM) OMT (Oral) HIV-1/2 rapid test has been formally accepted. The Company submitted its application to the BDA on December 27, 2005. According to Chinese drug registration regulations, the BDA is responsible for receiving applications on behalf of the State Food and Drug Administration of China (SFDA). Formal acceptance means that the BDA has completed an initial review of the application and deems the application to be sufficiently complete and in compliance with regulations to allow the application to advance into the formal review process. ADVERTISEMENT
Roger Gale, Chairman and Chief Executive Officer of Calypte said, "China is one of the countries that may experience a significant spread of HIV unless the government can follow through on its plans to curtail the growth of this problem. China has an acknowledged testing gap and has officially announced plans to offer voluntary HIV testing to its entire 1.36 billion-population, with particular emphasis on certain key groups, for which we believe our test is particularly appropriate. We believe that the only effective way to manage such testing thresholds is to utilize trained non-professionals to administer a program based on safe, non-blood or alternative fluid -- oral fluid -- testing."
Dr. Ron Mink, Chief Science Officer of Calypte added, "With the acceptance of our application by the BDA, Calypte has accomplished a key milestone in obtaining approval to sell our Aware(TM) HIV 1/2 OMT Rapid oral fluid product in the Chinese market. We believe that this product will have great appeal in China by virtue of its superior performance, competitive cost and advantages afforded by the use of oral fluid samples over other products available now or anticipated in the near future, in China."
About China:
China has a population of approximately 1.4 billion. According to a joint China, World Health Organization and UNAIDS epidemiological survey there were a reported 840,000 adults and children in China living with HIV/AIDS in 2003. Some experts have predicted that the number of infections by 2010 might exceed 15 million. The annual AIDS testing level is currently estimated at 1.5% of the population but is expected to grow -- partially due to a formal focus on mandatory testing in large markets such as population control, prisons and immigration and partially due to the Chinese government's program to offer voluntary HIV testing to its entire population.
Posted by Topcat on :
up 30% in Pre-market......
Posted by Poker Time on :
Bring it on....
Posted by Topcat on :
up 50% now !!!!!!!!!!!
Posted by Poker Time on :
Great news!!!..I saved a bunch of money on my car ins. by switching to Geico
Posted by metal1 on :
not quite China approval yet but it should still be good.
Posted by R1Man on :
I dropped the ball on this one....tried to pinch a penny and get in at $0.14 instead of taking the $0.15 a month ago with $3,000 for a long position.
Posted by R1Man on :
Maybe it will once again see the $1's before the years end providing it doesn't get DELISTED.
Posted by crusader30 on :
R1Man, I hope you got back in. This has been an incredible week. 1.36 Billion Chinese lining up to be tested. You may be looking at $1 through your rear view mirror.
Posted by Topcat on :
Going down again this week until we get full china approval, may take 90 days.....
Heard that sales contracts already there between Marr and Chinesse gov.....
Posted by Topcat on :
closed at .25 up 16% for the day.
May be good for a few swing plays the next few days.
I'm still goin hold the bulk of mine, in at .17
TC
Posted by Topcat on :
Yahoo! My Yahoo! Mail Make Yahoo! your home page Sign In New User?Sign Up Finance Home - Help
Welcome [Sign In] To track stocks & more, Register Financial News Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup
Calypte Introduces Over-the-Counter Rapid Oral HIV Test Thursday January 19, 8:00 am ET Aware(TM) OMT (Oral Fluid) HIV-1/2 Rapid Diagnostic Test Registered in the United Arab Emirates
LAKE OSWEGO, Ore., Jan. 19 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV - News) today announced the introduction of an over-the- counter (OTC) version of the Aware(TM) Oral Fluid HIV-1/2 Rapid Diagnostic Test. Calypte expects to initially launch the sale of this product in over-the-counter markets in the United Arab Emirates, where the product has been registered, and then plans to distribute it throughout the entire Middle East as additional registrations and/or approvals are obtained. ADVERTISEMENT
The OTC Aware Oral Fluid HIV-1/2 Rapid Diagnostic Test will be distributed by Joseph and Gionis, Calypte's exclusive distributor for 22 Middle Eastern countries with a population of approximately 465 million people. According to the December 2004 UNAIDS report, there are between 230,000 and 1.5 million adults and children living with HIV within this region, of which nearly half are women.
Mr. Roger Gale, Chairman and Chief Executive Officer of Calypte stated, "We are extremely pleased to launch our newest product, an Aware Oral Fluid HIV-1/2 Rapid Diagnostic Test designed for use in an over-the-counter setting. We believe that this product will add another tool to increase detection and combat the spread of HIV virus and that the combination of an over-the-counter product with safe, oral fluid detection is well suited to reach the greatest number of individuals within the Middle Eastern countries. We look forward to a productive relationship with our newest distributor, Joseph and Gionis, as it continues to utilize its expertise in regulatory pharmaceutical and governmental affairs to facilitate the regulatory process in additional countries within its territory."
Mr. Gale, concluded, "Our launch of this over-the-counter product coincides with Arab Health, the largest Healthcare Exhibition in the Middle East, being held in Dubai, January 22-25th. We have already shipped the initial order to Joseph and Gionis in conjunction with this Exhibition and we believe we have sufficient inventory in stock to satisfy anticipated initial sales of this innovative product."
About Joseph and Gionis LLC
Joseph and Gionis is a global biotechnology consulting and distribution firm with offices in Newport Beach, California and the United Arab Emirates, specializing in new scientific developments which contribute to public health and welfare.
About Calypte Biomedical:
Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent filings with the SEC.
Company Contact: Investor Relations Contact: Theodore R Gwin, Tim Clemensen, Chief Financial Officer Rubenstein Investor Relations (971) 204-0282 Phone: (212) 843-9337 email: tgwin*calypte.com email
Posted by crusader30 on :
Today should be very exciting Posted by Topcat on :
Time to protect your money !!
Glad I got out 2 weeks ago at .28
Notice of Delisting or Transfer
ITEM 3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING. On February 2, 2006 Calypte Biomedical Corporation (the "Company") received a letter from the American Stock Exchange (the "Exchange") notifying the Company that it does not satisfy certain of the Exchange's continued listing standards as set forth in Part 10 the American Stock Exchange Company Guide (the "Company Guide") and that the Exchange staff has, therefore, determined to initiate delisting proceedings with respect to the Company's common stock.
Specifically, the Exchange noted that the Company is not in compliance with Section 1003(a)(i) with shareholders' equity of less than $2,000,000 and losses from continuing operations and/or net losses in two out of its three most recent fiscal years; Section 1003(a)(ii) with shareholders' equity of less than $4,000,000 and losses from continuing operations and/or net losses in three out of its four most recent fiscal years; Section 1003(a)(iii) with shareholders' equity of less than $6,000,000 and losses from continuing operations and/or net losses in its five most recent fiscal years; and Section 1003(a)(iv) with losses which are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the Exchange, as to whether the Company will be able to continue operations and/or meet its obligations as they mature.
The Company has until February 10, 2006 to request an appeal of the Exchange's determination, and plans to request a hearing before a committee of the Exchange. The Company expects that such a hearing would be scheduled within 45 days of its request. There can be no assurance that the Company's appeal will result in the continued listing of its common stock on the Exchange. If its common stock is delisted from the Exchange after the hearing, it would likely trade on the NASD Over the Counter Bulletin Board.
Posted by R1Man on :
quote:Originally posted by Topcat: Time to protect your money !!
Glad I got out 2 weeks ago at .28
Notice of Delisting or Transfer
ITEM 3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING. On February 2, 2006 Calypte Biomedical Corporation (the "Company") received a letter from the American Stock Exchange (the "Exchange") notifying the Company that it does not satisfy certain of the Exchange's continued listing standards as set forth in Part 10 the American Stock Exchange Company Guide (the "Company Guide") and that the Exchange staff has, therefore, determined to initiate delisting proceedings with respect to the Company's common stock.
Specifically, the Exchange noted that the Company is not in compliance with Section 1003(a)(i) with shareholders' equity of less than $2,000,000 and losses from continuing operations and/or net losses in two out of its three most recent fiscal years; Section 1003(a)(ii) with shareholders' equity of less than $4,000,000 and losses from continuing operations and/or net losses in three out of its four most recent fiscal years; Section 1003(a)(iii) with shareholders' equity of less than $6,000,000 and losses from continuing operations and/or net losses in its five most recent fiscal years; and Section 1003(a)(iv) with losses which are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the Exchange, as to whether the Company will be able to continue operations and/or meet its obligations as they mature.
The Company has until February 10, 2006 to request an appeal of the Exchange's determination, and plans to request a hearing before a committee of the Exchange. The Company expects that such a hearing would be scheduled within 45 days of its request. There can be no assurance that the Company's appeal will result in the continued listing of its common stock on the Exchange. If its common stock is delisted from the Exchange after the hearing, it would likely trade on the NASD Over the Counter Bulletin Board.
This is a good thing....stocks that get delisted open for nothing then shoot up huge!
Posted by Topcat on :
Wait to get back in til after the company gets delisted so...
45 days artical above states.
Posted by Topcat on :
This is a good thing....stocks that get delisted open for nothing then shoot up huge!
Can you explain whay you mean by the above ??
Down another 10% this morning ......
Posted by metal1 on :
news out today......
Calypte Receives African Order for Aware(TM) HIV-1/2 Oral Fluid Rapid Tests
MineSeeker to Supply AIDS Tests in Africa
LAKE OSWEGO, Ore., July 13 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) (the "Company"), medical diagnostic tests manufacturer for the professional point of care (PRO) and over the counter (OTC) segments of the market for the detection of antibodies to the human immunodeficiency virus (HIV), announced today that it has received an initial order for 35,500 units of its Aware(TM) HIV-1/2 oral fluid rapid test. This initial order has been placed through Gennaria Comercio International Lda on behalf of MineSeeker Foundation and will be sold through Calypte's exclusive distributors in Africa once final destinations are known. Calypte currently has approval to sell its rapid oral fluid test in South Africa and Kenya. Based on Calypte's communications with MineSeeker, this is the first firm order of a series of orders totaling 1.0 million tests that MineSeeker intends placing with Calypte over the next 12 months.
Gennaria represents several humanitarian organizations, including MineSeeker, which plans to launch a large-scale HIV testing initiative in Africa beginning this September.
Nelson Mandela said: "As a patron of MineSeeker, I totally support the AIDS test initiative. The tests will remove the fear of many people who believe they may be infected and who are nervous about blood testing. Fear is a terrible affliction, whether it is the fear of treading on a mine or the fear not knowing if you are HIV positive."
Roger I. Gale, Calypte's Chairman and Chief Executive Officer commented, "We have long believed we have been developing an effective solution in the battle against HIV/AIDS with a non-invasive rapid diagnostic test. Now that we are receiving approvals in HIV-stricken areas in Sub-Saharan Africa, we are targeting humanitarian organizations that want to make significant contributions in the fight against AIDS."
Mr. Mike Kendrick, founder of MineSeeker, stated, "The intended first order of 1 million tests is part of a larger MineSeeker initiative to deliver 5 million HIV oral fluid rapid tests to Africa. The purchase of the initial 1 million Aware(TM) HIV-1/2 oral swab rapid tests will be donated to NGOs for distribution in the field or sold, at cost."
Mr. Kendrick continued, "While the primary objective of MineSeeker is the eradication of land mines, we are also committed to the regeneration of the local communities. Without that, the clearance of mines is only part of the answer. Land will be returned to the people to grow food and a foster management program installed to help re-establish themselves. This will mean growing good quality crops that will lift the natural immunity system -- particularly helping AIDS sufferers. The introduction of the Aware(TM) product will help re-build the confidence of these communities."
About MineSeeker Foundation:
The MineSeeker Foundation (www.mineseeker.com) is primarily involved with the removal of land mines. The foundation has a new initiative, the 'Sole of Africa' initiative, which includes returning mine free land back to agriculture and an educational and empowerment program that trains local people to farm and vocational training for people unable to find work, including land mine and AIDS victims.
The MineSeeker Foundation Patrons include Nelson Mandela, Sir Richard Branson, Queen Noor of Jordon, Graca Machel, John Paul Dejoria and Brad Pitt. The Foundation is supported by other leading NGOs including 'Feed the Children', The International Youth Foundation and The Salvation Army.
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases such as the HIV-1 BED Incidence EIA and new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2005 and its subsequent filings with the SEC.
Company Contact:
Theodore R Gwin, Chief Financial Officer
(971) 204-0282
email:tgwin*calypte.com
Investor Relations Contact:
Tim Clemensen,
Rubenstein Investor Relations
Phone: (212) 843-9337
email:tclemensen*rubensteinir.com
Posted by Topcat on :
Bad news dropped to 0.11 yesterday,
Any idea how low will it go ??
Calypte to Withdraw its American Stock Exchange Common Stock Listing Monday July 31, 12:11 pm ET
LAKE OSWEGO, Ore., July 31 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV - News), medical diagnostic tests manufacturer for the professional point of care (PRO) and over the counter (OTC) segments of the market primarily for the detection of antibodies to the human immunodeficiency virus (HIV) announced today that it has filed a voluntary request with the American Stock Exchange ("Amex" or the "Exchange") to withdraw its common stock from listing on the Amex effective as soon as practicable in compliance with the rules and regulations of the Amex and the SEC. ADVERTISEMENT
The Exchange has previously advised the Company that it was not in compliance with Section 1003(a)(iii) of the Exchange's Company Guide with shareholders' equity of less than $6,000,000 and losses from continuing operations and/or net losses in its five most recent fiscal years; and Section 1003(a)(iv) with losses which are so substantial in relation to its overall operations or its existing financial resources, or its financial condition had become so impaired that it appears questionable, in the opinion of the Exchange, as to whether the Company would be able to continue operations and/or meet its obligations as they mature. In March 2006, the Company appealed the determination of the Exchange's staff to initiate delisting procedures in a hearing before a listing qualifications panel of the Amex Committee on Securities (the "Panel").
The Panel set July 31, 2006 as the date by which the Company must demonstrate that it had regained compliance with the Amex's continued listing standards. If the Company is unable to demonstrate at that time that it is in compliance with those standards, the Panel agreed that the Amex should immediately move to de-list the Company's common stock.
Roger I. Gale, Chairman and Chief Executive Officer of Calypte stated, "Although we are making progress with our financing efforts, the Company will not meet the Exchange's continued listing standards by the July 31, 2006 compliance date specified by the Panel. Accordingly, the Company has determined to remove its common stock from listing on the Amex as soon as practicable. The Company plans to provide an operational update in conjunction with the release of its second quarter financial results in the first part of August."
Following a required notice period, Calypte's common stock will no longer be listed on the Amex. At that time, the Company expects that its common stock will trade on the NASD Over the Counter Bulletin Board. The Company is in the process of obtaining a new trading symbol.
Posted by Topcat on :
Ticker not valid anymore any idea where i can find it ?
Posted by Topcat on :
![[Big Grin]](biggrin.gif)
I don't know who you are stranger but you called this one right. I got in at .20. This could be a nice ride. I'd been watching it earlier. We'll see where it goes.
![[Cool]](cool.gif)
![[Eek!]](eek.gif)
![[Roll Eyes]](rolleyes.gif)
![[Razz]](tongue.gif)